Reuters logo
BRIEF-Bristol-Myers Squibb says early responses seen with Sprycel in first and second line treatment of pediatric patients with chronic myeloid leukemia in chronic phase
June 5, 2017 / 11:26 AM / 6 months ago

BRIEF-Bristol-Myers Squibb says early responses seen with Sprycel in first and second line treatment of pediatric patients with chronic myeloid leukemia in chronic phase

June 5 (Reuters) - Bristol-Myers Squibb Co

* Early, durable responses seen with Sprycel (dasatinib) in first- and second-line treatment of pediatric patients with chronic myeloid leukemia in chronic phase (CP-CML)

* Bristol-Myers Squibb - ‍secondary endpoint greater than 75 percent for patients resistant to/ intolerant of imatinib, greater than 90 percent for patients newly diagnosed with CP-CML​

* Bristol-Myers Squibb Co - ‍sprycel was shown to have comparable safety profile in pediatric patients with CP-CML to that reported in adults with CP-CML​

* Bristol-Myers Squibb- ‍in study, there were no reported events of pleural/pericardial effusion, pulmonary edema/hypertension or pulmonary arterial hypertension related to Sprycel​

* Bristol-Myers Squibb- ‍largest prospective trial in pediatric chronic myeloid leukemia in chronic phase includes first formulation specifically developed for pediatric population​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below